{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-25-000018","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.166322+00:00","generated_at":"2026-05-24T23:15:39.006000+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M","bullets":["Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.","AVISE CTD trailing 12-mo ASP reached $411, a $75 increase per test.","FY net loss improved ~$8M YoY to ($15.1M); adjusted EBITDA loss improved ~$7M to ($10.1M).","Surpassed 1 million patients tested with AVISE CTD; launched new SLE and RA biomarker assays in Jan 2025.","Expects positive adjusted EBITDA in Q4 2025; Q1 2025 revenue at least $14.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-25-000018","json":"https://secwatch.observer/filing/0001274737-25-000018.json","markdown":"https://secwatch.observer/filing/0001274737-25-000018.md","text":"https://secwatch.observer/filing/0001274737-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473725000018/0001274737-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473725000018/exdx-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:15:39.006000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}